CLINICALLY SIGNIFICANT DRUG-INTERACTIONS WITH THE ORAL ANTICOAGULANTS

被引:44
作者
FREEDMAN, MD
OLATIDOYE, AG
机构
[1] Johns Hopkins University School of Medicine, Baltimore, Maryland
[2] Sinai Hospital of Baltimore, Baltimore, Maryland
[3] Department of Internal Medicine, Section of General Internal Medicine, Sinai Hospital of Baltimore, Baltimore, Maryland, 21215
关键词
D O I
10.2165/00002018-199410050-00003
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Oral anticoagulants were introduced in the late 1940s and remain widely used today. Indications include prevention of thrombosis associated with atrial fibrillation, structural cardiac diseases and following prosthetic valvular replacement. They have been used for both treatment and prophylaxis of deep venous thrombosis and in efforts to decrease the frequency and rate of second myocardial infarction. These compounds include the coumarin derivatives [dicoumarol (bishydroxycoumarin), phenprocoumon, nicoumalone (acenocoumarol)] and the indanedione derivatives (diphenadione, phenindione. anisindione) which, because of adverse reactions, are largely unavailable. The oral anticoagulants, and warfarin in particular, are highly interactive with other drugs. Mechanisms of those interactions include both pharmacokinetic and pharmacodynamic mechanisms and may result in either hyper- or hypoprothrombinaemia. Because their principal adverse reaction is haemorrhage, and interactions are widespread across many therapeutic specialties, it becomes imperative for the practising physician to be aware of the possibility of interaction whenever these agents are coadministered with other drugs.
引用
收藏
页码:381 / 394
页数:14
相关论文
共 152 条
  • [1] Ahmad S., Lovastatin warfarin interaction, Archives of Internal Medicine, 150, (1990)
  • [2] Almog S., Martinowitz U., Halkin H., Bank H.Z., Farfel Z., Complex interactions of rifampin and warfarin, Southern Medical Journal, 81, pp. 1304-1306, (1988)
  • [3] Artrong G., Bed M.F., Scahill S., Warfarin potentiated by proguanil, British Medical Journal, 303, (1991)
  • [4] Baciewicz A.M., Morgan P.J., Ranitidine-warfarin interaction, Annals of Internal Medicine, 112, pp. 76-77, (1990)
  • [5] Bailey R.R., Reddy J., Potentiation of warfarin action by sulfinpyrazone, Lancet, 1, (1980)
  • [6] Banfield C., O'Reilly R., Chan E., Rowland M., Phenylbutazone-warfarin interactions in man: further sterochemical and metabolic considerations, British Journal of Clinical Pharmacology, 16, pp. 669-675, (1983)
  • [7] Bartle W.R., Blakely J.A., Potentiation of warfarin anticoagulation by acetaminophen, Journal of the American Medical Association, 265, (1991)
  • [8] Bechtold H., Evidence for impaired hepatic vitamin K<sub>1</sub> metabolism in patients treated with N-methylthiotetrazole cephalosporins, Thrombosis and Haemostatsis, 51, pp. 358-361, (1984)
  • [9] Bell W.R., Anderson K.C., Noe D.A., Silver B.A., Reduction in the plasma clearance rate of Warfarin induced by cimetidine, Archives of Internal Medicine, 146, pp. 2325-2328, (1986)
  • [10] Biggs R., Bangham D.R., Standardization of the one stage prothrombin time test for the control of anticoagulant therapy: the availability and use of thromboplastin reference preparations, Thrombosis et Diathesis Heamorrhagica, 26, (1971)